Literature DB >> 25599699

Everolimus-eluting stent implantation versus repeat paclitaxel-coated balloon angioplasty for recurrent in-stent restenosis lesion caused by paclitaxel-coated balloon failure.

Shunsuke Kubo1, Kazushige Kadota, Suguru Otsuru, Daiji Hasegawa, Seiji Habara, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Harumi Katoh, Tsuyoshi Goto, Kazuaki Mitsudo.   

Abstract

AIMS: Although paclitaxel-coated balloon (PCB) angioplasty has been reported to be effective for in-stent restenosis (ISR) lesions, the optimal treatment for recurrent ISR lesions caused by PCB failure remains unclear. This study compared clinical and angiographic outcomes after everolimus-eluting stent (EES) implantation and repeat PCB angioplasty for PCB failure. METHODS AND
RESULTS: From November 2008 to October 2011, we performed PCB angioplasty for 599 ISR lesions, of which 93 recurrent ISR lesions underwent EES implantation (53 lesions, 52 patients) or repeat PCB angioplasty (40 lesions, 37 patients). The choice of treatment strategy was decided at the operatorÕs discretion. Angiographic outcomes were evaluated by follow-up angiography at six to eight months after procedure. The baseline characteristics were similar between the two groups. At follow-up angiography (93.5% of all lesions), minimum lumen diameter was significantly larger and the binary restenosis rate was significantly lower after EES implantation than after repeat PCB angioplasty (2.08±0.79 mm vs. 1.45±0.68 mm, p<0.001; 20.0% vs. 54.1%, p=0.001; respectively), whereas late lumen loss was not different between the two groups (0.49±0.62 mm vs. 0.59±0.74 mm, p=0.47). At two years, the incidences of both target lesion revascularisation (TLR) and clinically driven TLR were significantly lower after EES implantation than after repeat PCB angioplasty (17.9% vs. 57.5%, p=0.001; 5.9% vs. 18.1%, p=0.01; respectively).
CONCLUSIONS: EES implantation was more effective for PCB failure in preventing subsequent TLR than repeat PCB angioplasty because of better angiographic results.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25599699     DOI: 10.4244/EIJV10I9A180

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  5 in total

1.  Initial and late efficacy of everolimus-eluting stents for small and non-small coronary lesions from evaluating delayed late loss study.

Authors:  Naoto Tama; Hiroyasu Uzui; Yuki Horita; Masanobu Namura; Hiroshi Tada
Journal:  Heart Vessels       Date:  2017-07-07       Impact factor: 2.037

2.  Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment.

Authors:  Viviane Gouveia; Dinaldo C Oliveira; Emmanuele Tenorio; Norma Brito; Emanuel Sarinho
Journal:  Cardiol Res       Date:  2016-06-24

Review 3.  Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis.

Authors:  Wen-Juan Xiu; Hai-Tao Yang; Ying-Ying Zheng; Yi-Tong Ma; Xiang Xie
Journal:  Cardiol Res Pract       Date:  2018-07-24       Impact factor: 1.866

Review 4.  Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis.

Authors:  Kong-Yong Cui; Shu-Zheng Lyu; Min Zhang; Xian-Tao Song; Fei Yuan; Feng Xu
Journal:  Chin Med J (Engl)       Date:  2018-03-05       Impact factor: 2.628

Review 5.  Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients.

Authors:  Daniele Giacoppo; Giuseppe Gargiulo; Patrizia Aruta; Piera Capranzano; Corrado Tamburino; Davide Capodanno
Journal:  BMJ       Date:  2015-11-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.